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IL2 is frequently given alongside adoptive cell therapy
in order to enhance T cell function and survival, how-
ever, the protein has a poor pharmacokinetic profile
and severe negative side effects. Fc-IL2 is a monovalent
Fc fusion with IL2. The addition of the Fc domain to
the cytokine significantly improved the persistence of
the molecule in vivo, leading to enhanced activation of
many types of immune cells, including T cells. The
treatment described here is the combination of ACT,
Fc-IL2, and/or antibodies targeting tumor associated
antigens. The application of these three agents in pre-
clinical experiments showed increased persistence of
transferred cells, extended survival of treated animals,
regression of tumor size (see Figure 1), and in some
cases complete cures of established tumors with
immune memory, as demonstrated by the rejection of
secondary tumor challenge. Although the combination
of all three agents was the most effective, the survival
benefit of ACT and Fc-IL2 without antibody was sig-
nificant enough to justify its use regardless of the
availability of appropriate antibodies. The experimental
model consisted of C57BL/6 mice subcutaneously
injected with the B16F10 cell line. Following tumor
establishment for 6 days, patient mice were lymphode-
pleted by total body irradiation and treated with a sin-
gle injection of pmel-1 T cells, which express a T cell
receptor (TCR) specific for B16F10 cells. In addition,
over the next 24 days, 5 injections of Fc-IL2 and an
antibody specific for B16F10 cells, TA99, were per-
formed. Luciferase expressing pmel-1 cells were also
injected in order to track the duration and intensity of
the T cell response to the B16F10 tumors. These
results show that effective adjuvants, such as Fc-IL2,
have the potential to improve the clinical outcomes of
adoptive cell therapy.
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Figure 1 Growth curves of B16F10 tumors treated with
combination immunotherapy.
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